European Biotech Acquisition Corp.

European Biotech Acquisition Corp., trading under the ticker EBAC, is a blank-check company formed to pursue a merger, capital stock exchange, asset acquisition, or similar business combination with a target in the European biotechnology and life sciences sector. The SPAC completed its initial public offering in 2021 and filed a Form 10-Q with the SEC on November 23, 2021, under accession number 0001193125-21-337192, reflecting its active search phase. EBAC positioned itself to capitalize on the depth of European biotech innovation, a space that has drawn sustained institutional interest. Sign up for SpacDesk to access EBAC's full filing history, deal timeline, and comparable SPAC data.